Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4

3(60.0%)

N/A

1(20.0%)

Phase 2

1(20.0%)

5Total

Phase 4(3)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05679570Phase 2Active Not Recruiting

Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)

Role: lead

NCT07038551Phase 4Recruiting

Prophylactic Use of Naldemedine on Opioid-induced Nausea and Vomiting in Patients With Cancer: POSEIDON Study

Role: lead

NCT06611696Phase 4Recruiting

Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis

Role: collaborator

NCT06943417Not ApplicableNot Yet Recruiting

Safety and Efficacy of Endoscopic Full Thickness Biopsy in Patients With Chronic Intestinal Pseudo-obstruction

Role: lead

NCT05703464Phase 4Terminated

Elobixibat for Chronic Constipation Without Defecation Desire

Role: lead

All 5 trials loaded